4basebio (LON:4BB) Shares Down 5.5% – Here’s What Happened

4basebio PLC (LON:4BB)’s stock price traded down 5.5% on Thursday . The stock traded as low as GBX 519.75 and last traded at GBX 519.75. 2 shares changed hands during trading, a decline of 100% from the average daily volume of 1,415 shares. The stock had previously closed at GBX 550.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada reduced their price objective on shares of 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating for the company in a research note on Monday, June 15th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, 4basebio presently has an average rating of “Buy” and an average target price of GBX 1,400.

4basebio Stock Down 1.0%

The firm has a market capitalization of £80.48 million, a PE ratio of -4.77 and a beta of 1.09. The company has a debt-to-equity ratio of 201.47, a current ratio of 2.73 and a quick ratio of 3.52. The company has a 50-day moving average price of GBX 523.46 and a 200 day moving average price of GBX 525.25.

4basebio (LON:4BB) last released its earnings results on Wednesday, May 20th. The company reported GBX (1.09) earnings per share (EPS) for the quarter. The company had revenue of GBX 169 million during the quarter. Analysts forecast that 4basebio PLC will post -3.43 earnings per share for the current year.

Insider Buying and Selling

In other 4basebio news, insider Amy Walker acquired 1,863 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average cost of GBX 509 per share, with a total value of £9,482.67. 12.08% of the stock is owned by company insiders.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.